MIT and Harvard reserchers have developed immune-evading CAR-NK cells that eliminate cancer in mice while avoiding cytokine release syndrome.
CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, presented at the Cold ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...
Artiva Biotherapeutics, Inc. (($ARTV)) announced an update on their ongoing clinical study. Artiva Biotherapeutics, Inc. is conducting a Phase 2a ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback